Acute Intermittent Porphyria Market

 Market Overview:

The 7 major acute intermittent porphyria markets reached a value of US$ 1.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.46% during 2024-2034.

The acute intermittent porphyria market has been comprehensively analyzed in IMARC's new report titled "Acute Intermittent Porphyria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute intermittent porphyria (AIP) is a rare genetic condition that impairs the body's ability to produce heme, a molecule essential for the function of many enzymes and the formation of hemoglobin in red blood cells. Some of the common symptoms of AIP are abdominal pain, nausea, vomiting, constipation, diarrhea, etc. Various other signs indicative of the disease can include tingling or numbness in the limbs, muscle weakness, psychiatric disturbances, such as anxiety or depression, seizures, respiratory failure, etc. Diagnosing acute intermittent porphyria (AIP) can be challenging, as its symptoms can be non-specific and overlap with those of other medical conditions. The diagnosis of AIP is typically based on a combination of factors, including the person's medical history, physical exam, laboratory tests, and genetic testing. Numerous diagnostic procedures help identify abnormal levels of porphyrins in the urine, blood, and stool, and genetic testing aids in confirming the presence of mutations in the porphobilinogen deaminase (PBGD) gene. In some cases, a liver biopsy may be performed to assess the extent of porphyrin accumulation in the liver.

The increasing incidence of rare metabolic disorders and the rising prevalence of numerous associated risk factors, including excessive alcohol consumption, hormonal changes, certain medications, etc., are primarily driving the acute intermittent porphyria market. Furthermore, the escalating utilization of several biomarkers, such as urinary porphobilinogen and aminolevulinic acid levels, to confirm AIP and monitor disease activity is also bolstering the market growth. In addition to this, the growing focus on raising disease awareness among healthcare professionals, patients, and the general public to ensure that individuals with AIP receive timely and appropriate care is further augmenting the market. Moreover, various key players are making extensive investments in the development of novel drugs and therapies for AIP, including those that target specific enzymes involved in heme biosynthesis or modulate the immune system. This, in turn, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of next-generation sequencing to screen for multiple genes associated with AIP, which can help identify rare genetic variants that may be missed by conventional genetic testing, is creating a positive outlook for the market. Furthermore, ongoing advancements in the formulation technology of hematin have led to the introduction of more convenient and easier-to-use hematin products, including lyophilized powder and ready-to-use liquid formulations. This, in turn, is expected to drive the acute intermittent porphyria market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the acute intermittent porphyria market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute intermittent porphyria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute intermittent porphyria market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute intermittent porphyria market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute intermittent porphyria market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute intermittent porphyria marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the acute intermittent porphyria market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acute intermittent porphyria market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acute intermittent porphyria market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of acute intermittent porphyria across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of acute intermittent porphyria by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of acute intermittent porphyria by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with acute intermittent porphyria across the seven major markets?
• What is the size of the acute intermittent porphyria patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute intermittent porphyria?
• What will be the growth rate of patients across the seven major markets?
   

Acute Intermittent Porphyria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute intermittent porphyria drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute intermittent porphyria market?
• What are the key regulatory events related to the acute intermittent porphyria market?
• What is the structure of clinical trial landscape by status related to the acute intermittent porphyria market?
• What is the structure of clinical trial landscape by phase related to the acute intermittent porphyria market?
• What is the structure of clinical trial landscape by route of administration related to the acute intermittent porphyria market?